Nautilus Biotechnology, Inc. Lease, Cost
Nautilus Biotechnology, Inc. (NAUT) reported Lease, Cost of $10.63 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-02-26
- Nautilus Biotechnology, Inc. lease, cost for the quarter ending 2023-12-31 was $2.62M, a 61.93% increase year-over-year.
- Nautilus Biotechnology, Inc. lease, cost for the quarter ending 2023-09-30 was $2.44M, a 50.71% increase year-over-year.
- Nautilus Biotechnology, Inc. lease, cost for the quarter ending 2023-06-30 was $2.45M, a 56.12% increase year-over-year.
- Nautilus Biotechnology, Inc. lease, cost for the quarter ending 2023-03-31 was $1.82M, a 11.75% increase year-over-year.
- Nautilus Biotechnology, Inc. lease, cost for fiscal 2025 was $10.63M, a 4.91% increase from fiscal 2024.
- Nautilus Biotechnology, Inc. lease, cost for fiscal 2024 was $10.14M, a 8.71% increase from fiscal 2023.
- Nautilus Biotechnology, Inc. lease, cost for fiscal 2023 was $9.32M, a 45.00% increase from fiscal 2022.
- Nautilus Biotechnology, Inc. lease, cost for fiscal 2022 was $6.43M, a 55.87% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $10.63M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $10.14M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $2.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $5.06M derived: sum of 2 quarters · filed 2025-02-27 | $7.51M derived: sum of 3 quarters · filed 2025-02-27 | $9.32M 10-K · filed 2025-02-27 |
| 2023-09-30 | $2.44M 10-Q · filed 2023-10-31 | $4.89M derived: sum of 2 quarters · filed 2023-10-31 | $6.71M 10-Q · filed 2023-10-31 | $8.32M derived: sum of 4 quarters · filed 2024-02-28 |
| 2023-06-30 | $2.45M 10-Q · filed 2023-08-02 | $4.26M 10-Q · filed 2023-08-02 | $5.88M derived: sum of 3 quarters · filed 2024-02-28 | $7.50M derived: sum of 4 quarters · filed 2024-02-28 |
| 2023-03-31 | $1.82M 10-Q · filed 2023-05-02 | $3.44M derived: sum of 2 quarters · filed 2024-02-28 | $5.05M derived: sum of 3 quarters · filed 2024-02-28 | $6.62M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $3.24M derived: sum of 2 quarters · filed 2024-02-28 | $4.80M derived: sum of 3 quarters · filed 2024-02-28 | $6.43M 10-K · filed 2024-02-28 |
| 2022-09-30 | $1.62M 10-Q · filed 2023-10-31 | $3.19M derived: sum of 2 quarters · filed 2023-10-31 | $4.81M 10-Q · filed 2023-10-31 | $6.45M derived: sum of 4 quarters · filed 2023-10-31 |
| 2022-06-30 | $1.57M 10-Q · filed 2023-08-02 | $3.19M 10-Q · filed 2023-08-02 | $4.83M derived: sum of 3 quarters · filed 2023-08-02 | $5.82M derived: sum of 4 quarters · filed 2023-08-02 |
| 2022-03-31 | $1.63M 10-Q · filed 2023-05-02 | $3.26M derived: sum of 2 quarters · filed 2023-05-02 | $4.25M derived: sum of 3 quarters · filed 2023-05-02 | $5.06M derived: sum of 4 quarters · filed 2023-05-02 |
| 2021-12-31 | $1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $2.62M derived: sum of 2 quarters · filed 2023-02-23 | $3.44M derived: sum of 3 quarters · filed 2023-02-23 | $4.13M 10-K · filed 2023-02-23 |
| 2021-09-30 | $992.00K 10-Q · filed 2022-11-01 | $1.80M derived: sum of 2 quarters · filed 2022-11-01 | $2.49M 10-Q · filed 2022-11-01 | $3.02M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $812.00K 10-Q · filed 2022-08-02 | $1.50M 10-Q · filed 2022-08-02 | $2.02M derived: sum of 3 quarters · filed 2022-08-02 | $2.53M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $690.00K 10-Q · filed 2022-05-03 | $1.21M derived: sum of 2 quarters · filed 2022-05-03 | $1.72M derived: sum of 3 quarters · filed 2022-05-03 | $2.23M derived: sum of 4 quarters · filed 2022-05-03 |
| 2020-12-31 | $521.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $1.03M derived: sum of 2 quarters · filed 2022-02-24 | $1.54M derived: sum of 3 quarters · filed 2022-02-24 | $2.12M 10-K · filed 2022-02-24 |
| 2020-09-30 | $511.00K 10-Q · filed 2021-11-02 | $1.02M derived: sum of 2 quarters · filed 2021-11-02 | $1.59M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $511.00K 10-Q · filed 2021-08-10 | $1.08M 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |